• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Elise Mak

Articles by Elise Mak

Duke-NUS brings aboard Novo Nordisk to fund stem cell research program

May 17, 2018
By Elise Mak
HONG KONG – Denmark's Novo Nordisk A/S has teamed up with Singapore's Duke-NUS Medical School to provide funding for the next three to five years for stem cell-based research aimed at growing heart muscle and retinal cells to treat heart failure and vision loss.
Read More

With $11M, Syntekabio will advance bioinformatics and AI platforms

May 16, 2018
By Elise Mak
HONG KONG – South Korean bioinformatics company Syntekabio Inc. pocketed $11.2 million in a series B financing to advance two of it core platforms in bioinformatics and AI-driven drug discovery to speed up drug development process.
Read More

Asymchem inks deal aiming to bring foreign drugs into China

May 16, 2018
By Elise Mak
HONG KONG – China's Asymchem Laboratories (Tianjin) Co. Ltd. joined hands with a top private equity firm and two government-backed parties to spearhead drug innovation in the northeastern city of Tianjin to bring novel drugs from overseas into the Chinese market.
Read More

Ascletis becomes first biopharma to file under new HKEX listing rules

May 16, 2018
By Elise Mak
HONG KONG – Hangzhou, China-based Ascletis Pharma Inc. became the first pre-revenue biotech startup to seek public listing in Hong Kong last week. The company plans to use the proceeds to advance its two hepatitis C drug candidates into commercialization in China.
Read More

What's happening at Sinovac? Vaccine business disrupted by dispute over privatization

May 16, 2018
By Elise Mak
HONG KONG – Nasdaq-listed Chinese vaccine maker Sinovac Biotech Ltd. is on the brink of collapse, as it is undergoing a series of events due to internal disputes concerning its privatization. The company has put its vaccine productions on hold, which may soon have an impact on its business.
Read More

Asymchem inks deal aiming to bring foreign drugs into China

May 15, 2018
By Elise Mak
HONG KONG – China's Asymchem Laboratories (Tianjin) Co. Ltd. joined hands with a top private equity firm and two government-backed parties to spearhead drug innovation in the northeastern city of Tianjin to bring novel drugs from overseas into the Chinese market.
Read More

Ascletis becomes first biopharma to file under new HKEX listing rules

May 10, 2018
By Elise Mak
HONG KONG – Hangzhou, China-based Ascletis Pharma Inc. became the first pre-revenue biotech startup to seek public listing in Hong Kong this week. The company plans to use the proceeds to advance its two hepatitis C drug candidates into commercialization in China.
Read More

What's happening at Sinovac? Vaccine business disrupted by dispute over privatization

May 10, 2018
By Elise Mak
HONG KONG – Nasdaq-listed Chinese vaccine maker Sinovac Biotech Ltd. is on the brink of collapse, as it is undergoing a series of events due to internal disputes concerning its privatization. The company has put its vaccine productions on hold, which may soon have an impact on its business.
Read More

PwC finds med-tech industry M&A on an upward trend in China

May 9, 2018
By Elise Mak

South Korea's pricing policies could put pressure on novel drugs

May 9, 2018
By Elise Mak
HONG KONG – While the South Korean government's pricing regime is helping to make drugs more affordable in the country, it is also slowing the value growth of the pharmaceutical market and pressuring the sales of innovative drugs.
Read More
Previous 1 2 … 74 75 76 77 78 79 80 81 82 83 84 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 8, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • Illustration of cancer tumor on pancreas

    PIKfyve enzyme is target to ‘starve’ pancreatic cancer cells

    BioWorld
    A metabolic vulnerability of pancreatic ductal adenocarcinoma (PDAC) could be used to address this type of cancer that often resists treatments. Scientists at the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe